SGLT2 inhibitors are a favourable treatment option for neutropaenia and neutrophil dysfunction in GSD Ib, and result in improved bowel and gum health with an overall improvement in laboratory markers. The gene discussed is SLC5A2; the disease is disorder of glycogen metabolism.